Stockscreener 앱 받기
39.80
2.27%
-0.925
시간 외 거래:
39.17
-0.625
-1.57%
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
(RVMD) Investment Report - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN) - The Globe and Mail
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $37.82 - knoxdaily.com
Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan
Revolution Medicines, Inc. to Report Q1 2025 Financial Results on May 7, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - AOL.com
Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Revolution Medicines (RVMD) Reports Promising Data for Zoldonras - GuruFocus
A Guide To The Risks Of Investing In Revolution Medicines Inc (RVMD) - knoxdaily.com
Revolution Medicines Shares Rise on 'Encouraging' Phase 1 Lung Cancer Trial Data - marketscreener.com
Revolution’s Next KRAS Drug Shows Promise In NSCLC - insights.citeline.com
AACR 2025: Revolution has early stage KRAS success in NSCLC - BioWorld MedTech
Perhaps timely catching Revolution Medicines Inc (RVMD) would be a good idea - Sete News
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC - GuruFocus
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting | RVMD Stock News - GuruFocus
Revolution Medicines Reports Promising Clinical Data for Zoldonrasib in KRAS G12D Mutant Non-Small Cell Lung Cancer at AACR Annual Meeting - Nasdaq
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - GlobeNewswire
Revolutionary KRAS Cancer Drug Achieves 61% Response Rate in Lung Cancer PatientsKey Trial Data Released - Stock Titan
Russell Investments Group Ltd. Increases Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Revolution Medicines Inc (RVMD) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
RVMD Stock Sees Surge of Approximately 3.08% in Last Five Days - knoxdaily.com
This trade activity should not be overlooked: Revolution Medicines Inc (RVMD) - Sete News
Revolution Medicines Inc [RVMD] stock was sold by Cislini Jeff at the price of US$79008.0 - knoxdaily.com
Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire
(RVMD) Trading Signals - news.stocktradersdaily.com
Revolution Medicines at Stifel Forum: RAS-Driven Cancer Insights By Investing.com - Investing.com Canada
Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines stock hits 52-week low at $30.02 - Investing.com Australia
Revolution Medicines at Needham Conference: Progress in Cancer Treatment - Investing.com Australia
Revolution Medicines at Needham Conference: Progress in Cancer Treatment By Investing.com - Investing.com Canada
Revolution Medicines stock hits 52-week low at $30.02 By Investing.com - Investing.com India
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $39.97 - knoxdaily.com
When the Price of (RVMD) Talks, People Listen - news.stocktradersdaily.com
Revolution Medicines (NASDAQ:RVMD) Price Target Lowered to $64.00 at Stifel Nicolaus - Defense World
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Revolution Medicines to Deliver Multiple Presentations at - GlobeNewswire
Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan
Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - MSN
Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan
Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com
Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia
Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia
Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada
Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India
Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com
Revolution Medicines Executives Sell Shares - TradingView
0.39%
3.66%
자본화:
|
볼륨(24시간):